Lazard Asset Management’s Coherus Oncology, Inc. Common Stock CHRS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-883,729
| Closed | -$919K | – | 2313 |
|
|
2024
Q3 | $919K | Buy |
883,729
+252,982
| +40% | +$263K | ﹤0.01% | 1108 |
|
|
2024
Q2 | $1.09M | Buy |
630,747
+243,047
| +63% | +$420K | ﹤0.01% | 959 |
|
|
2024
Q1 | $926K | Buy |
387,700
+374,307
| +2,795% | +$894K | ﹤0.01% | 937 |
|
|
2023
Q4 | $44K | Sell |
13,393
-443,192
| -97% | -$1.46M | ﹤0.01% | 1914 |
|
|
2023
Q3 | $1.71M | Sell |
456,585
-93,938
| -17% | -$351K | ﹤0.01% | 893 |
|
|
2023
Q2 | $2.35M | Buy |
550,523
+173,190
| +46% | +$739K | ﹤0.01% | 861 |
|
|
2023
Q1 | $2.58M | Buy |
377,333
+59,611
| +19% | +$408K | ﹤0.01% | 869 |
|
|
2022
Q4 | $2.52M | Buy |
317,722
+156,746
| +97% | +$1.24M | ﹤0.01% | 872 |
|
|
2022
Q3 | $1.55M | Buy |
160,976
+152,754
| +1,858% | +$1.47M | ﹤0.01% | 932 |
|
|
2022
Q2 | $59K | Sell |
8,222
-14,666
| -64% | -$105K | ﹤0.01% | 1736 |
|
|
2022
Q1 | $295K | Sell |
22,888
-23,486
| -51% | -$303K | ﹤0.01% | 1194 |
|
|
2021
Q4 | $740K | Buy |
46,374
+38,531
| +491% | +$615K | ﹤0.01% | 1047 |
|
|
2021
Q3 | $126K | Sell |
7,843
-14,374
| -65% | -$231K | ﹤0.01% | 1363 |
|
|
2021
Q2 | $307K | Sell |
22,217
-62,859
| -74% | -$869K | ﹤0.01% | 1152 |
|
|
2021
Q1 | $1.24M | Buy |
85,076
+25,179
| +42% | +$368K | ﹤0.01% | 870 |
|
|
2020
Q4 | $1.04M | Buy |
+59,897
| New | +$1.04M | ﹤0.01% | 887 |
|
|
2017
Q3 | – | Sell |
-49,100
| Closed | -$704K | – | 989 |
|
|
2017
Q2 | $704K | Buy |
+49,100
| New | +$704K | ﹤0.01% | 682 |
|